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Abstract
Both external and internal exposure to ionizing radiation are strong risk factors for the development
of thyroid tumors. Until now, the diagnosis of radiation-induced thyroid tumors has been deduced
from a networkof arguments taken togetherwith the individual history ofradiation exposure. Neither
thehistologicalfeaturesnorthegenetic alterationsobservedinthesetumorshavebeenshowntobe
speciﬁc ﬁngerprints of an exposure to radiation. The aim of our work is to deﬁne ionizing radiation-
relatedmolecularspeciﬁcities inaseriesofsecondarythyroidtumors developedintheradiation ﬁeld
of patients treated by radiotherapy. To identify molecular markers that could represent a radiation-
induction signature, we compared 25K microarray transcriptome proﬁles of a learning set of 28
thyroid tumors, which comprised 14 follicular thyroid adenomas (FTA) and 14 papillary thyroid
carcinomas(PTC),eithersporadicorconsecutivetoexternalradiotherapyinchildhood.Weidentiﬁed
a signature composed of 322 genes which discriminates radiation-induced tumors (FTA and PTC)
from their sporadic counterparts. The robustness of this signature was further conﬁrmed by blind
case-by-case classiﬁcation of an independent set of 29 tumors (16 FTA and 13 PTC). After the
histology code break by the clinicians, 26/29 tumors were well classiﬁed regarding tumor etiology, 1
wasundetermined,and2weremisclassiﬁed.Ourresultshelpshedlightonradiation-inducedthyroid
carcinogenesis, since speciﬁc molecular pathways are deregulated in radiation-induced tumors.
Endocrine-Related Cancer (2011) 18 193–206
Introduction
The link between external radiation during childhood
and thyroid cancer has been known since 1950 (Duffy
& Fitzgerald 1950); until recently this was the only
demonstrated etiological risk factor for thyroid cancers
(Ron et al. 1995). A higher incidence of thyroid cancer
has been reported in epidemiological studies after
either internal or external exposure to radiation
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commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.(Ron et al. 1995, Cardis et al. 2005). A pooled analysis
of seven studies established that the excess relative risk
of thyroid cancer in subjects irradiated at a young age
was very high – 7.7 per Gray (Gy) – the risk being
signiﬁcant for radiation doses as low as 0.1 Gy and
increasing linearly with increasing doses (Ron et al.
1995). It has been estimated that 88% of thyroid
carcinomas occurring in subjects exposed to radiation
doses equal to 1 Gy during childhood are radiation-
induced. The risk of developing a thyroid carcinoma is
the highest 15–30 years after exposure, but is still
present after more than 40 years (Ron et al. 1995). If
exposure occurred in adulthood, the risk is much lower
(Richardson 2009).
In parallel, a worldwide increase in thyroid tumors,
mainly PTC, has been observed over the last 30 years
(Enewoldetal.2009).Thishasledtodebateconcerninga
potential link with changes in environmental exposure
linked to nuclear tests, the nuclear industry, and, in
Western Europe, Chernobyl disaster fallout. Some data
suggest that this increase is at least partly related to the
routine screening of thyroid nodules using neck
ultrasound and ﬁne needle biopsy, which permit the
detection of small papillary carcinomas that would
otherwise have gone undetected (Leenhardt et al.2 0 0 4 ,
Colonna etal.20 07 ). Thishighprevalenceofsuchsmall
cancers had already been reported in autopsy studies
(Harachetal.19 85 ,Yamamotoetal.19 90 ).However,it
is not possible to exclude the possibility that some of
these thyroid tumors could have been radiation-induced.
Radiation-induced thyroid tumors have no speciﬁc
histological characteristics (Rubino et al.2 0 0 2 ,
Williams et al.2 0 0 8 ). They are either follicular thyroid
adenomas(FTA)orpapillarythyroidcarcinomas(PTC).
These histological subtypes are also the most frequent
sporadic thyroid tumors. For these reasons, it is of
major interest to identify speciﬁc ﬁngerprints of thyroid
cancer developing after thyroid radiation exposure that
would indicate, with a high probability, the etiology of
any tumor. Molecular differences between sporadic and
radiation-induced thyroid tumors were sought using
microarray transcriptome analysis. The ﬁrst study,
including sporadic and post-Chernobyl PTC, did not
show any speciﬁc radiation-induced gene expression
signature (Detours et al.2 0 0 5 ). However, the authors
were able to classify their series of tumors by using a
signature that was previously found to discriminate
between irradiated- and hydrogen-peroxide-treated
lymphocytes (Detours et al. 2007). Others studies
found radiation-induced signatures in post-Chernobyl
PTC (Port et al.2 0 0 7 , Stein et al.2 0 1 0 ), but without
blind validation of the signature. A recent study
compared cell cycle protein expression in sporadic and
post-radiotherapy PTC, but none of the tested markers
could be associated with the etiology (Achille et al.
2009), while combinations of protein markers such as
matrix metalloproteinases, cathepsins, and neurotrophic
tyrosine kinase receptor 1 allowed discrimination of
post-Chernobyl PTC as a function of etiology by
immunostaining (Boltze et al.2 0 0 9 ). Together, these
studies must be considered as preliminary and others
should be analyzed to establish a robust characterization
of the gene expression differences between sporadic
and radiation-induced PTC (rPTC).
Theaimofthisstudyistodeﬁnetheionizingradiation-
related molecular speciﬁcities of human thyroid
tumors developing in the radiation ﬁeld of patients
treated with radiotherapy. We compared the transcrip-
tome proﬁles of sporadic and radiation-induced FTA
(rFTA) and rPTC (nZ28) obtained after hybrization
on 25K oligonucleotide microarrays and identiﬁed a
signature of 322 genes that discriminated between
radiation-induced tumors (FTA and PTC) and their
sporadic counterparts. The blind classiﬁcation of an
independent set of 29 tumors using this signature led to
thecorrectclassiﬁcationof26/29tumorsregardingtumor
etiology, 1 was undetermined, and 2 were misclassiﬁed.
Materials and methods
Tumor samples
Fifty-sevenfrozentumorswereobtainedfromtheInstitut
G us t a v eR o us s ya ndt h eN i c eH u m a nB i o ba n k( C a nc e ´ro-
pole PACA and CRB INSERM, CHU Nice, France;
Tables1and2).Histopathologicdiagnosiswasperformed
according to the WHO guidelines. The series comprised
12 rPTCs, 15 rFTAs, 15 sporadic PTCs (sPTCs), and 15
sporadic FTAs (sFTAs). Sporadic tumors were matched
by histology, age at diagnosis, and tumor, nodes,
metastasis (TNM) classiﬁcation. Radiation exposure
wasspeciﬁcallyinvestigatedineachpatientbyexamining
theirmedicalrecordsand/orbypostalcontact.Allpatients
were Caucasian except one who was African black.
Tumors from patients who were exposed to external
radiation were considered as radiation-induced accor-
ding to Cahan’s criteria (Cahan et al.1 9 4 8 ): 1) after
radiotherapy, the second neoplasm must arise in the
irradiated ﬁeld and be proved histologically; 2) a latent
period of several years must have elapsed between
radiation exposure and development of the second
neoplasm;and3)thesecondtumormustbehistologically
different from the ﬁrst tumor. Several patients also
received chemotherapy for the treatment of their
primary tumors as shown in Tables 1 and 2.P a t i e n t s
hospitalized at the Pasteur Hospital (Department of
C Ory, N Ugolin et al.: Gene signature of radiation-induced thyroid tumors
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www.endocrinology-journals.org 195Otorhinolaryngology, Nice, France) gave their signed
agreement to participate in the study. The protocol was
approvedbythelocalethicscommitteeoftheUniversity
of Nice (‘Comite ´ de Protection des Personnes’ and the
DRCVIofthe CHUofNice) and bythe FrenchMinistry
of Research (N8DC-2008-391 and N8AC-2008-83).
Written informed consent was obtained fromall patients
at the Institut Gustave Roussy and the study was
performed in accordance with protocols previously
approved by the ethics committee of Bice ˆtre and by the
Institutional Review Board of Institut Gustave Roussy.
Calculation of the dose received by the
thyroid gland
The approach and software used for retrospective
dose evaluations has been previously detailed in
Diallo et al. (1996, 2009). Technical data concerning
the radiotherapy procedure were obtained from radio-
therapy records. Direct individual radiotherapy dose
calculations were performed using the homemade
Dos_EG software package (Diallo et al. 1996).
For each patient, a simple mathematical phantom
anatomy was generated according to patient dimen-
sions. The shape of external contours and lungs were
modeled by means of basic geometric forms. One
hundred and eighty-eight sites of interest were
speciﬁed as points within the phantom. Among these,
three were localized at the thyroid. One of these points
represents the isthmus and the two others represent the
left and right lobes respectively. To calculate the dose
to an anatomic site, beams were positioned on the
phantom according to details from the patient’s record,
Table 2 Clinical data for sporadic tumors
Patient Histology Sex
Age at
tumor
diagnosis
(years)
Genic
alterations Ethnicity
Tumor
size (mm) Chemotherapy Detected by
Learning/training set
SA1 FTA F 59 C 26 K Screening
SA2 FTA M 63 C 30 K Screening
SA3 FTA M 48 C 20 K Screening
SA4 FTA F 22 C 40 K Screening
SA5 FTA M 44 HRAS Q61R C 33 K Incidental ﬁnding
SA6 FTA M 24 C 55 K Screening
SA7 FTA M 21 NRAS Q61R C 45 K Incidental ﬁnding
SP1 PTCFV F 54 BRAF V600E C 50 K Screening
SP2 PTC F 27 BRAF V600E C 10 K Screening
SP3 PTC F 25 C 20 K Screening
SP4 PTCFV F 44 RET/PTC3 C 32 K Screening
SP5 PTC F 39 BRAF V600E C 18 K Screening
SP6 PTC F 34 RET/PTC1 C 13 K Incidental ﬁnding
SP7 PTC F 23 BRAF V600E C 23 K Incidental ﬁnding
MeanZ37 MeanZ29
Testing set
XA1 FTA M 58 C 35 K Incidental ﬁnding
XA2 FTA F 31 C 20 K Screening
XA3 FTA F 29 C 13 K Screening
XA4 FTA F 29 C 15 K Screening
XA5 FTA F 27 C 30 K Screening
XA6 FTA F 59 C 26 K Screening
XA7 FTA F 22 NRAS Q61K C Unavailable K Screening
XA8 FTA F 48 C 38 K Screening
XP1 PTC F 17 BRAF V600E C 30 K Screening
XP2 PTC F 25 C 25 K Screening
XP3 PTC F 39 C 20 K Screening
XP4 PTC F 17 RET/PTC1 C 10 K Screening
XP5 PTC M 74 BRAF V600E C 25 K Screening
XP6 PTCFV F 73 BRAF 3 bp Del C 17 K Screening
XP7 PTCFV M 41 C 55 K Screening
XP8 PTC F 40 BRAF V600E C 20 K Screening
MeanZ39 MeanZ25
FTA,follicularthyroidadenoma;PTC,papillarythyroidcarcinoma;PTCFV,papillarythyroidcarcinoma,follicularvariant;C,Caucasian.
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treatment techniques, and guidelines used at the time
of the treatment. Radiotherapy parameters included
beam size, shape and inclination, location, radiation
energy, and delivered treatment dose. The dose
calculation algorithm accounted for primary radiation
from the treatment machine and scattered radiation
from the patient and from beam collimation, leakage
radiation, and lung heterogeneity. The local radiation
dose at a site was deﬁned as the cumulative absorbed
dose resulting from the contribution of all beams
involved in the radiotherapy regimen. For all patients
who received radiotherapy for a primary cancer, the
doses received by the thyroid gland were calculated
and are presented in Table 1.
Mutation analysis
RET/PTC1 and RET/PTC3 rearrangements were
detected by RT-PCR as described in Smida et al.
(1999).M u t a t i o n so fBRAF and HRAS, KRAS,a n d
NRAS genes were analyzed by cDNA sequencing
(Beckman Coulter Genomics (Cogenics), Grenoble,
France) after PCR ampliﬁcation. Primer sequences are
listed in Supplementary Table 1, see section on
supplementary data given at the end of this article.
RNA extraction, labeling, and hybridization
TheprotocolforRNAextraction,RNAampliﬁcation,and
labeling was as described in Daino et al. (2009). Quality
of RNA was assessed using the RNA 6000 Nano Lab-
On-Chip as developed on the Agilent 2100 Bioanalyzer
device (Agilent Technologies, Palo Alto, CA, USA).
All specimens included in this study displayed an RNA
integrity number over 7.7. Each tumor sample was
co-hybridized with a common pool of ampliﬁed normal
thyroid RNA used as a reference, and all hybridizations
were duplicated in dye-swap. Samples were hybridized in
500 mlo f2 ! SSC (Gibco), 0.1% SDS (Gibco),
5 mg salmon sperm DNA (Invitrogen) on human 25K
50–52mer oligo-microarrays from a national genomic
platform (Resogen Program, RNG/MCR, Evry). Spotted
slides were prepared as recommended by the manu-
facturer. The arrays were incubated overnight at 50 8C
in an Agilent hybridization oven. After hybridization, the
slides were successively washed for 5 min with agitation
in 2! SSC plus 0.1% SDS, 1! SSC, 0.2! SSC, and
0.05! SSC, then dried by centrifugation.
Preprocessing of microarrays
The procedure for array scanning, calculation of ﬂuo-
rescence intensities, data normalization, and statistical
analysis were performed as described previously
(Chevillard et al. 2004) with modiﬁcations (Bastide
et al. 2009, Daino et al. 2009). All data is deposited in
Array Express database (http://www.ebi.ac.uk/arrayex-
press/, E-MEXP-2739).
Search for molecular signature of tumor etiology
The thyroid tumors were split into 2 sets: a
learning/training set, used to search for the molecular
signature,thiscomprisedof7rFTAs,7sFTAs,7rPTCs,
and 7 sPTCs, and a testing set, which comprised of
the remaining 29 tumors (16 FTAs and 13 PTCs as
testing tumors), used for blind classiﬁcation. At the
time of the blind classiﬁcation the tumor histology,
but no radiation exposure history, was known.
The method for classifying the etiology comprised
the following four steps:
1) A learning step, based on a classiﬁcation
expectation–maximization algorithm, to select
sets of candidate genes whose expression
discriminates between the two subgroups
(Daino et al. 2009);
2) a training step to select from the sets of candidate
genes those with the highest potential to classify
training tumors correctly (Dudoit et al. 2002);
3) the compilation of a unique discriminating set of
genes and standardization of their expressions
according to gene expression variability in the
subgroups; and
4) theblindclassiﬁcation,case-by-case,oftestingtumors.
Learning step
Combinatorial matrices of 8 tumors (4 sFTAs or sPTCs
out of the 14 sporadic cases versus 4 rFTAs or rPTCs
out of the 14 radiation-induced cases) were built from
the learning/training set of tumors, the 20 remaining
tumors of each combinational matrix being used as
training tumors. To avoid bias due to histology, each
half matrix (four sporadic or radiation-induced tumors)
should include at least one tumor of each histology,
either FTA or PTC. In the same way, to avoid bias due
to tumor size and speciﬁcally to microcarcinomas, we
split the tumors of the learning group into three
categories: group 1 size %25th percentile (12 mm);
group 2 size O25th percentile and !75th percentile
(30 mm); and group 3 size R75th percentile. The
tumor size distribution in group 2 was similar for
sporadic and radiation-induced tumors, whatever the
histology, PTC or FTA. Each half matrix should also
contain at least one tumor of group 2 size and should
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composition. With these rules, we excluded any impact
of size or tumor histology in the signature. Finally,
81 8-tumor training matrices were considered.
Training step
Each training matrix was used to classify, by a
two-step principal component analysis (PCA) method
(see ‘Blind classiﬁcation by a two-step PCA
method’), the 20 remaining tumors from the
respective combinatorial matrix (training tumors).
Then, the rules to select a matrix were applied so
that at least one of the training tumors was well
classiﬁed and none were misclassiﬁed, otherwise the
matrix was discarded. This was performed for each
training matrix. The process continued if at least 90%
of the training tumor classiﬁcations were validated by
at least one of the training matrices. In these
conditions, 10% of the tumors may not be validated,
but none must be rejected by the retained training
matrices. The training step selected 26 matrices that
were able to classify at least one training tumor,
without false classiﬁcation.
Compilation of a unique discriminating set of genes
The 26 selected training matrices (e) were compiled
in a unique x matrix. Among the 974 genes
belonging to the x matrix, we ﬁnally retained, for
the ﬁnal gene signature, in a x0 matrix, 322 genes as
function of a threshold (PZ0.001) on the frequencies
of relevance, which is deﬁned as the frequency at
which a given gene and a given tumor are found
together in a selected training matrix, weighted by
the number of training tumors well classiﬁed by this
training matrix. Then, the relevance of the 322 genes
of the ﬁnal signature was proved by blind classi-
ﬁcation of the 29 testing tumors by a two-step PCA
method. All the method is detailed in Supplementary
Table 2, see section on supplementary data given at
the end of this article.
Blind classiﬁcation by a two-step PCA method
Let us deﬁne g and T as x0 matrix and a given validation
tumor respectively or a given training matrix and a
corresponding given training tumor respectively. The
eigenvectors and eigenvalues were calculated for the
considered g matrix. These vectors deﬁned a new space
maximizing speciﬁcally the asymmetry between the
two groups of tumors (sporadic or radiation-induced)
of the matrix (classiﬁcation space). The classiﬁcation
of a T tumor was then realized by its location in the
classiﬁcation space, compared with the location of the
two subgroups of tumors of the g matrix.
When taking into account more than three eigen-
vectors, to assess more precisely the distances between
the vectors, we used a decision-making tool based on
calculation of the root mean square (Supplementary
Table 2, see section on supplementary data given at the
end of this article).
Results
To search for a signature of thyroid tumor etiology,
we have conducted a 25K microarray transcriptome
analysis on a series of sporadic and radiation-induced
benign and malignant thyroid tumors. For blind
classiﬁcation of new tumors, we developed a unique
strategy based on an expectation-maximisation algo-
rithm that identiﬁes a gene expression signature with
the greatest potential to discriminate between the two
subgroups of tumors in a learning/training set, and on a
two-step PCA analysis, which deﬁnes an N dimensional
classiﬁcation space that presents the greatest asymmetry
between the two subgroups.
Identiﬁcation of the discriminating signature
between radiation-induced and sporadic tumors
To increase the likelihood that the tumors used to search
the signature are radiation-induced and not sporadic,
we paid special attention to the choice of patients and
tumors included in the learning group. Only patients
treated before 15 years of age, which is considered
the period of high thyroid radiation sensitivity, were
included in the learning/training set of tumors (Table 1).
Moreover, to prevent any bias due to multiple
comparison failure, patients with sporadic tumors were
selected to match, as far as possible, sex, ethnicity, and
ageattumordiagnosisofpatientswithradiation-induced
tumors (Tables 1 and 2). Mean age at tumor diagnosis
was 38 vs 40 years old for rFTA and sFTA and 32 vs 35
yearsoldforrPTCandsPTCrespectively.Inthelearning
set, the female to male ratio was 1.8 (9/5 females/males)
in sporadic tumors and 2.5 (10/4 females/males) in
radiation-induced tumors (Tables 1 and 2).
A four-step method (learning, training, compilation
of a unique discriminating set of genes, and blind
classiﬁcation of new tumors) was applied to a
learning/training set of 28 tumors (FTA or PTC) of
known etiology, sporadic, or radiation-induced, which
included 7 rFTA, 7 sFTA, 7 rPTC, and 7 sPTC. When
considering sporadic and radiation-induced tumors as
the two subgroups in the search for a signature,
whatever the histological subtypes (FTA or PTC),
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to be differentially expressed when comparing the two
groups. This set included 137 overexpressed and 185
underexpressed radiation-induced tumors as compared
with sporadic tumors (Supplementary Table 3, see
section on supplementary data given at the end of this
article). The Cartesian coordinate system, deﬁned by
the two-step PCA method, determined the testing–
classiﬁcation space, which was found to be organized
as three subspaces, corresponding to the sFTA, the
sPTC, and all radiation-induced tumors of the learning
set (Fig. 1).
In order to check that this molecular signature of
tumor etiology was not speciﬁc to some DNA
mutations, we searched for RAS, RET/PTC,a n d
BRAF genetic alterations in the learning/training set
of tumors (Tables 1 and 2). Mutations at codon 61 of
NRAS, HRAS,o rKRAS were found in one rFTA and
two sFTA. RET/PTC rearrangements were identiﬁed in
two sPTC and BRAF mutations were detected in four
sPTC and one rPTC (with no overlap with RET
rearrangements). Thus, it is unlikely that the signature
could be speciﬁc to any type of mutation.
To understand the molecular speciﬁcities of radi-
ation-induced thyroid tumorigenesis, we searched for
the biological function and relationship between the
322 genes of the discriminating signature (Supple-
mentary Table 3, see section on supplementary data
given at the end of this article). However, to be more
exhaustive in the overview of the radiation-induced
deregulated pathways, we also included the 651
preselected genes found during the training step to be
deregulated (Supplementary Table 4, see section on
supplementary data given at the end of this article).
While not included in the ﬁnal signature, these genes
were able to classify tumors in several combinations of
tumors of the learning/training set without misclassiﬁ-
cation (see Materials and methods section).
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Figure 1 Blind validation of the radiation-induced signature by
PCA analysis in the classiﬁcation space deﬁned by the tumors
of the learning/training set. By the two-step PCA method, the
tumors of the learning set, being FTA (red triangle) and PTC
(green circle), either sporadic (empty symbols) or radiation-
induced (full symbols), deﬁned a validation space in which each
tumor of the testing set is projected to identify its etiology. The
ﬁgure represents examples of the relative positioning of four
testing tumors (blue square) in this validation space. (A) A well-
classiﬁed rPTC (XP11), (B) a well-classiﬁed sFTA (XA6), (C)
the outlier rPTC tumors (XP9), positioned in the validation
space between the rPTC and sPTC subgroups.
(D) A misclassiﬁed sFTA (XA1). Values of tumors used for
hypothesis ﬁnding in (A–D) seem to differ slightly. This is an
artifact due to data representation in two dimensions.
The validation space is deﬁned in ten dimensions, according to
the tumors of the learning/training set, and each tumor of the
validation set is projected in this space to be classiﬁed.
To visualize the results of tumor classiﬁcation, the space is
restrained tothreedimensions and projectedin twodimensions.
During this reduction, the relative localization of the tumors
could appear slightly modiﬁed.
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Using this signature, a two-step PCA analysis was used
for blind classiﬁcation of the 29 tumors of the testing
set. Patient and tumor characteristics are given in
Tables 1 and 2. For blind validation of the molecular
signature, each testing tumor was projected into the
classiﬁcation space, allowing us to propose an etiology
depending on the relative positioning of the testing
tumors compared with the learning/training tumors
(Fig. 1). This signature was robust, since it correctly
predicted the etiology of 26 of the 29 tumors. Six of the
eight sFTA, the eight rFTA, the eight sPTC, and four of
the ﬁve rPTC were well classiﬁed. One rPTC (XP9)
was clusterized between the group of sPTC and the
group of radiation-induced tumors, so it was not
possible to propose an etiology for this tumor (Fig. 1C),
and two sFTA (XA1, Fig. 1A and XA8) were classiﬁed
among the radiation-induced tumors. Since these
tumors developed in patients without known history
of radiation exposure, these may be false results but,
alternatively, these patients may have high thyroid
sensitivity and may have been exposed to ionizing
radiation in the past. In any case, the present signature
of thyroid tumor etiology has a very good negative
predictive value, as all testing tumors diagnosed as
sporadic were indeed sporadic tumors and the signature
has a rather good positive predictive value, as 12 of
the 14 radiation-induced testing tumors were well
diagnosed (1 and 0.85 respectively).
It should be mentioned that using a similar approach
we also searched for a signature of tumor etiology in
each histological subtype. We found two distinct gene
expression signatures discriminating sFTA and rFTA,
and sPTC and rPTC but, due to the small number of
tumors, we did not have enough samples to check the
validity of these signatures by blind classiﬁcation of
an independent series of tumors (data not shown).
Discussion
Most methods used to analyze microarray data wish to
identify groups of genes that have coherent patterns of
expression with large variance across groups of
samples. Unfortunately, using these methods, we did
not ﬁnd any signature of etiology. Gene shaving is a
useful alternative method, which uses PCA to ﬁnd the
space direction which captures the majority of variance
in the whole data set and thus permits the identiﬁcation
of those genes which are able to separate the two
groups of tumors, whatever the variance of individual
gene expression. Unfortunately, gene shaving is not
suitable for a small series of samples, such as our series
of tumors. For this reason, we have developed a
method based on a similar strategy to that of gene
shaving, which is adapted to a small number of
samples. It allows us to ﬁnd the space direction, which
maximizes, if they exist, the criteria discriminating the
two groups of tumors.
Post-radiotherapy tumors (R-tumors)
The choice of R-tumors, speciﬁcally those used for
the learning/testing step, was crucial for the veracity
of the results. Due to the high frequency of sporadic
thyroid tumors in the general population, we followed
very stringent criteria to minimize the risk of
including a sporadic tumor (S-tumor) in the group of
R-tumors: we strictly followed Cahan’s criteria for
R-tumor selection. Moreover, these tumors should
have developed in children who were exposed to
radiotherapy while younger than 15, since this
corresponds to the period of highest thyroid radiation
sensitivity (Steliarova-Foucher et al. 2006). Regarding
the risk as a function of the dose received at the
thyroid gland, it was shown that, in this age range, the
relative risk at 1 Gy was estimated at 8.7 and
the attributable risk at 1 Gy was estimated to be
88% (Ron et al. 1995). At 1–15 Gy to the thyroid, the
relative risk was found to be 3.5 if radiotherapy
occurred before 10 years, and 0.9 if it occurred later,
the risk then decreases following a symmetrical curve,
consistent with a cell killing effect (Sigurdson et al.
2005). The relative risk for doses of about 40 Gy is 5
and the attributable risk 80% (Sigurdson et al. 2005).
It should be estimated that after thyroid radiation
exposure during childhood or adolescence, at doses
from 20 to 40Gy, the expected frequency of radiation-
induced tumors ranged from 80 to 90%. Therefore, 1
of 14 tumors of the R-learning group may be sporadic.
Therefore, to evaluate the consequence, if an S-tumor
was unfortunately included in the R-group, we have
mimicked the situation by searching a signature using a
learning set composed of 13 R-tumors plus 1 S-tumor
(‘false R’-tumor) versus 14 S-tumors (data not shown).
Overall,duetotheverystringentmethodappliedforgene
selection,mostoftenwedidnotﬁndasignatureandwhen
itwasfoundthe‘falseR’-tumorsystematicallylocalized
between the two groups of R- and S-tumors. This
situation could have consequences if tumors of the
validation set were classiﬁed only as a function of this
‘false R’-tumor. In fact, we could have raised the
questionregardingRA7(learningtumor),sinceXA1and
XA8 (validation tumors) are considered misclassiﬁed
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border of the R-group (Fig. 1D).
Regarding the thyroid radiosensitivity in adulthood,
itshouldbementionedthatfourtumorsofthevalidation
group, which are classiﬁed as R-tumors, developed
in patients who received radiotherapy at 30, 35, 36,
and 37 years old. These data are in agreement with the
fact that although the risk of radiation-induced thyroid
cancer decreases as age increases, the excess of relative
risk per gray is still positive up to 40 years old (Ron
et al. 1995). It should be mentioned that in a cohort
of patients developing secondary radiation-induced
thyroid tumors, 11 of 27 patients received chemo-
therapy for their primary tumor (Table 1). Importantly,
for the validity of the data, it was shown that
chemotherapy for the ﬁrst cancer was not associated
with thyroid cancer risk and it did not modify the effect
of radiotherapy (Sigurdson et al. 2005).
Our study is the ﬁrst transcriptome analysis of
post-radiotherapy radiation-induced thyroid tumors.
We found a robust molecular signature of thyroid
tumor etiology – demonstrated by the correct blind
classiﬁcation of 26 of 29 tumors. Few studies on
transcriptome analysis of post-Chernobyl thyroid
tumors have been published. In this study, most of
the patients were externally exposed to radiation to treat
Hodgkin’s disease or non-Hodgkin lymphoma. The
estimated mean dose received by the thyroid gland
varies between 0.1 and 43 Gy in repeated exposure at
high-dose rates (Table 1). In contrast, after the
Chernobyl accident, victims’ thyroids were mainly
chronically contaminated by
131I ingestion. In the
exposed population, the cumulative thyroid radiation
doses ranged from 0.02 Gy to more than 10 Gy, but
mostpeoplereceiveddoseslessthan1 Gy.Alow-iodine
diet in the exposed population was reported to be an
importantparameterinthe developmentofthesetumors
(Williams et al. 2008). The relevance of extrapolation
of conclusions from data on tumors occurring after
exposuretoexternalradiationtopost-Chernobyltumors
thatoccurredafterinternal
131Icontaminationisunclear.
An overlap was found between post-radiotherapy
deregulated genes, identiﬁed in this study, and post-
Chernobyl deregulated genes. EPB41L3,at u m o r
suppressor included in the 322-gene signature, and
RERG, C13ORF33, GZMH, MST150, RARRES1,
RIPK4, and SFRP1, found in the enlarged set, were
reported in a set of deregulated genes in post-
Chernobyl PTC (Port et al. 2007). Genes such as
ABI2, COL4A5, FAT3, IGFBP3, KRTAP3-2,a n d
SPOCK1 and several immunoglobulin chains were
deregulated in post-radiotherapy tumors, while genes
of the same family and/or function, such as ABI3,
COL4A6, FAT2, IGFBP1, KRTAP2-1, KRTAP2-4,
SPOCK2 and other immunoglobulin chains, were
also deregulated in the study of Port et al. (2007),
suggesting common deregulated pathways in post-
radiotherapy and post-Chernobyl tumors. Since we
also observed genes in common with another pre-
viously published post-Chernobyl series of thyroid
tumors (Detours et al. 2007), (genes from the sig-
nature: C4A, CLU; DCI, DHCR24, EGFR, EGR3,
GTF2H2, ICAM3, NRIP1, PLA2R1, and RPS19. From
the enlarged set: EFNA1, EIF2AK2, FAM38A, MED1,
MGEF8, PPL, SCARA3, SMO, and ZFHX4), several of
these genes could be potential markers of radiation-
induced thyroid tumors, independently of the histology
and the internal–external type of radiation exposure.
It should be mentioned that KLK10, underexpressed
in post-radiotherapy-induced thyroid tumors, was
also speciﬁcally identiﬁed as a downregulated gene in
radiation-transformed human mammary epithelial cells
(Liu et al. 1996).
Molecular speciﬁcities of
post-radiotherapy-induced tumors
Deregulated genes in radiation-induced tumors are
mostly involved in molecular mechanisms such as
cellular response to oxidative stress and irradiation,
response to hypoxia, regulation of p53 function,
immune response, and signal transduction pathways
including mitogen-activated protein kinase (MAPK),
epidermal growth factor receptor (EGFR), RAC/
CDC42, hedgehog, transforming growth factor
(TGF)/bone morphogenetic protein (BMP), calcium
signaling, and WNT canonical and noncanonical
pathways (Fig. 2). The WNT/b-catenin pathway has
already been implicated in normal thyroid function and
in thyroid carcinogenesis (Garcia-Rostan et al. 2001,
Castellone et al. 2009). Interestingly, genes known to
connect the WNT pathway with cellular response to
hypoxia (ARD1A; Lim et al. 2008), to the EGFR, TGF,
and NOCHT (TLE2) pathways (Buscarlet & Stifani
2007) were also found to be deregulated.
As described by Detours et al. (2007), we found that
radiation-induced tumors are imprinted by an oxidative
stress hallmark since deregulated genes such as CFL1,
CLU, DHCR24, FMOD, GSTM1-2, and PRNP are
involved in sensitivity to H2O2 or ionizing radiation
exposure. Interestingly, chronic oxidative stress is
known to provoke increasing chromosomal instability
(Abdel-Rahman 2008) and we observed that genes
regulating the G2/M phase and/or checkpoints (PTTG1,
SPAG5, DNAH9, C13orf3, NUP153, CENPE, CDCA8,
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radiation-induced tumors.
One of the central players in the cellular response to
DNA damage and in the maintenance of genome
integrity following cell exposure to oxidative stress is
the tumor suppressor p53. In thyroid cancer, a very low
frequency of TP53 mutations was observed in sporadic
and in post-Chernobyl tumors (Hillebrandt et al. 1996,
Nikiforov et al. 1996). However, p53 protein over-
expression was described, in PTC and anaplastic
thyroid carcinomas, not associated with gene mutation,
suggesting that other mechanisms may regulate p53 in
thyroid tumors (Soares et al. 1994, Malaguarnera et al.
2007). In radiation-induced tumors, a decrease in TP53
gene expression was observed, but it was not selected
in the highly discriminating signature (Fig. 3). Inter-
estingly, several genes involved in the regulation of
p53 turnover, p53 phosphorylation, and/or p53 tran-
scriptional activity were differentially expressed
depending on the etiology. This included some highly
discriminating genes of the signature, such as
MAPKAPK2, PARP1, IFI16, PTTG1, RAD32B, and
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Figure 2 Genes of the WNT canonical and noncanonical pathways deregulated in radiation-induced thyroid tumors. The ﬁgures
representa simpliﬁed overviewofWNTcanonicalpathwaywithpotentialconnections withEGFR,SHH,orNOTCHpathways(A)and
WNT noncanonical pathway (B). Genes overexpressed (green) or underexpressed (red), either in the discriminating signature (322
genes) or deregulated with less recurrence in post-radiotherapy tumors, are indicated by dark or light rectangles respectively.
Orange circles show genes found to be deregulated in post-Chernobyl tumors, while green diamonds indicate deregulated genes
in thyroid sporadic tumors (see Discussion section).
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stress, DNA damage, DNA repair, and genetic
stability. DHCR24, which protects p53 against
MDM2-dependent degradation following oxidative
stress (Kuehnle et al.2 0 0 8 ), has already been found
to be deregulated in Chernobyl tumors (Detours et al.
2007). The MDM2 gene is overexpressed in radiation-
induced tumors along with genes regulating its
function or stabilization, such as KAT5, TWIST2,
TSPYL2, MAPKAPK2, and HSPB1. Recent data have
pointed to a link between cancer, DNA damage
response, and circadian clock regulation (Sahar &
Sassone-Corsi 2009). Three genes involved in the
regulation of this pathway were found to be deregu-
lated (BHLHE40, ARNTL/BMAL1, and MYBBP1A),
suggesting that the circadian clock, which is physio-
logically regulated by, and regulates, the endocrine
functions of thyroid tissue, may be also be implicated
in radiation-induced tumorigenesis.
Finally, another feature of exposure of the thyroid
g l a n dt or a d i a t i o ni st h ei n c r e a s e df r e q u e n c yo f
autoimmune dysfunctions. In this respect, an
immunoglobulin kappa light chain variable region
(accession number L12079) was identiﬁed in patients
withGraves’disease(Chazenbalketal.1993),aswellas
genes involved in T lymphocyte function (POU2AF1,
CLECL1, IL2RG, CCL22, MADCAM1, LY75,a n d
TRAT1) were deregulated and thus could also be related
to the immune thyroid status of radiation-induced
tumors. In parallel, genes associated with thyroid
dysfunction or susceptibility to thyroid disease, such
as IGFBP3, DUOX2, NKX2 1/TTF1, GNA11, and
SLC26A4/pendrin (Moreno et al. 2002, Moya et al.
2006, Kero et al. 2007, Kopp et al. 2008, Kursunluoglu
et al. 2009), or with other autoimmune diseases, such as
IL17B,IRF4,LAIR2,andRC3H1,werealsoderegulated.
In conclusion, we found a highly speciﬁc post-
radiotherapy gene signature to diagnose thyroid tumor
etiology independently of histological subtype. Several
genes of this signature were also deregulated in post-
Chernobyl PTC, although the type of exposure, range of
dose, and other parameters such as iodine consumption
are different. It could be interesting, using our
methodology,tosearchforasignatureinpost-Chernobyl
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either in the discriminating signature (322 genes) or deregulated with less recurrence in post-radiotherapy tumors, are indicated by
dark or light rectangles respectively. Orange circles show genes found to be deregulated in post-Chernobyl tumors, while green
diamonds indicate deregulated genes in thyroid sporadic tumors (see Discussion section).
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www.endocrinology-journals.org 203thyroid tumors and indeed to assess the relevance of
our signature in classifying post-Chernobyl tumors
compared with sporadic tumors.
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